MBIO logo

MUSTANG BIO INC

MBIONASDAQ
🏆 #5234 by market capEarnings Nov 18US Equity
$0.49▼ $0.02 (−3.79%)
Live
🔔
Track MBIO
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.8%
7d▼ 2.5%
14d▼ 6.8%
30d▼ 9.3%
ytd▼ 50.5%
1y▼ 69.1%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
76
Good

Trading Snapshot

Day Range
$0.48 – $0.49
52-Week Range
$0.47 – $1.85
Volume
$2.13B
Avg Volume
$2.25B
Shares Outstanding
7.6M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$298,126
Last Q Revenue
$79,038
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.46
Dividend Yield
—
Dilution (1yr)
−16.0%

Why Investors Own MBIO

  • ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MBIO logo

MUSTANG BIO INC

MBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$2M▼ −85.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −53.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.3M▼ −16.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$17M▲ +$11M YoY
StockOtter · stockotter.space

About MUSTANG BIO INC

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$0.58
▲ +19.7% Upside
High Target$0.67
Low Target$0.51
Based on 35 analysts

Latest News & Updates

🚀
CNBC·2h ago

MUSTANG BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift MBIO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

MUSTANG BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.